tumour detection radiopharmaceuticals	are	imaging agents
tumour detection radiopharmaceuticals	target	malignant cells
tumour detection radiopharmaceuticals	bind	tumour receptors
tumour detection radiopharmaceuticals	emit	gamma rays
gamma rays	detected by	PET scanners
PET scanners	produce	3‑D images
3‑D images	reveal	tumour size
tumour size	predicts	prognosis
tumour detection radiopharmaceuticals	labeled with	technetium‑99m
technetium‑99m	has	half‑life 6 h
half‑life 6 h	limits	radiation dose
radiopharmaceuticals	used in	staging
staging	informs	treatment plan
treatment plan	guides	surgery
surgery	reduces	mortality
radiopharmaceuticals	used in	surveillance
surveillance	detects	recurrence
recurrence	increases	readmission risk
readmission risk	predicts	healthcare cost
radiopharmaceuticals	administered via	intravenous route
intravenous route	ensures	systemic distribution
systemic distribution	reaches	primary tumour
primary tumour	may express	HER2
HER2	is	therapeutic target
therapeutic target	linked to	trastuzumab
trastuzumab	improves	survival
survival	inversely related to	tumour burden
tumour burden	measured by	SUVmax
SUVmax	derived from	PET uptake
PET uptake	correlates with	Ki‑67
Ki‑67	indicates	proliferation rate
proliferation rate	predicts	aggressiveness
aggressiveness	affects	chemotherapy choice
chemotherapy choice	influences	toxicity
toxicity	impacts	quality of life
quality of life	measured by	ECOG score
ECOG score	predicts	overall survival
overall survival	is	key endpoint
radiopharmaceuticals	may contain	iodine‑123
iodine‑123	used for	thyroid imaging
thyroid imaging	detects	metastases
metastases	alter	staging
staging	determines	eligibility for immunotherapy
immunotherapy	includes	PD‑1 inhibitors
PD‑1 inhibitors	reduce	relapse rate
relapse rate	lowers	readmission frequency
readmission frequency	reduces	hospital burden
hospital burden	affects	resource allocation
resource allocation	influences	treatment access
treatment access	determines	patient adherence
patient adherence	predicts	treatment efficacy
treatment efficacy	reflected in	remission rate
remission rate	inversely related to	tumour volume
tumour volume	estimated by	volumetric analysis
volumetric analysis	uses	CT scans
CT scans	complement	PET imaging
PET imaging	enhances	diagnostic accuracy
diagnostic accuracy	reduces	misdiagnosis
misdiagnosis	leads to	inappropriate therapy
inappropriate therapy	increases	morbidity
morbidity	elevates	mortality risk
mortality risk	is	outcome metric
outcome metric	guides	clinical trials
clinical trials	evaluate	new tracers
new tracers	may target	PSMA
PSMA	expressed in	prostate cancer
prostate cancer	treated with	radioligand therapy
radioligand therapy	uses	lutetium‑177
lutetium‑177	emits	beta particles
beta particles	cause	tumour cell death
tumour cell death	reduces	tumour burden
tumour burden	lowers	PSA levels
PSA levels	monitor	disease activity
disease activity	informs	surveillance strategy
surveillance strategy	includes	repeat imaging
repeat imaging	detects	early progression
early progression	prompts	therapy adjustment
therapy adjustment	may involve	dose escalation
dose escalation	increases	side effect risk
side effect risk	managed by	supportive care
supportive care	improves	patient comfort
patient comfort	correlates with	adherence
adherence	predicts	long‑term survival
long‑term survival	measured by	5‑year survival
5‑year survival	depends on	initial tumour stage
initial tumour stage	determined by	imaging
imaging	includes	MRI
MRI	provides	soft‑tissue contrast
soft‑tissue contrast	aids	margin assessment
margin assessment	guides	resection completeness
resection completeness	affects	local recurrence
local recurrence	increases	re‑operation rate
re‑operation rate	raises	healthcare utilization
healthcare utilization	impacts	payer policies
payer policies	influence	drug reimbursement
drug reimbursement	determines	access to radiopharmaceuticals
access to radiopharmaceuticals	affects	diagnostic equity
diagnostic equity	linked to	socioeconomic status
socioeconomic status	predicts	health disparities
health disparities	drive	public health interventions
